Corporate | 18 November 2010 16:16
STRATEC Biomedical Systems AG / Key word(s): Miscellaneous
18.11.2010 16:16
---------------------------------------------------------------------------
STRATEC admitted into Deutsche Börse TecDAX(R)
Birkenfeld, November 18, 2010
STRATEC Biomedical Systems AG, Birkenfeld, Germany (Frankfurt: SBS; Prime
Standard) announces that its shares will be listed on the TecDAX(R) from
November 19, 2010, as published by Deutsche Börse on November 17, 2010.
This follows an unscheduled change in the index composition.
TecDAX(R) is the selection index of Deutsche Börse for mid-sized companies
from technology sectors. It starts directly below the DAX(R) and has 30
constituents which are admitted to the Prime Standard segment of the
Regulated Market.
Marcus Wolfinger, CFO of STRATEC Biomedical Systems AG commented: 'We are
delighted with Deutsche Börse's decision, which we believe reflects
STRATEC's positive operating performance in recent years. We are confident
that we will continue this upward trajectory in our business in the coming
years and will drive forward with active and transparent investor relations
activities.'
STRATEC has been listed on the stock market since 1998 and has been
included in the Prime Standard of Deutsche Börse since its inception.
During the company's successful development between 2000 and 2009, STRATEC
has generated average annual growth of 24% in sales and 55% in earnings.
The company's current medium-term guidance figures, originally published in
December 2009, foresee sales in 2010 in the range of EUR 96 million to EUR
102 million (2009: EUR 79.6 million) with an EBIT margin of at least 19%
(2009: 18.5%). The compound annual growth rate (CAGR) for sales over the
years 2010 to 2012 is expected to exceed 15%.
About STRATEC
STRATEC Biomedical Systems AG (www.stratec-biomedical.de) designs and
manufactures fully automated systems for its partners in the fields of
clinical diagnostics and biotechnology. These partners market such systems,
in general together with their own reagents, to laboratories, blood banks
and research institutes around the world. The company develops its products
on the basis of its own patented technologies. Shares in the company (ISIN:
DE0007289001) are traded in the Prime Standard segment of the Frankfurt
Stock Exchange.
The STRATEC Group consists of the publicly listed parent company STRATEC
Biomedical Systems AG and of subsidiaries and second-tier subsidiaries in
Germany, the USA, the UK, Switzerland and Romania.
Further information can be obtained from:
STRATEC Biomedical Systems AG
André Loy, Investor Relations
Gewerbestr. 37, 75217 Birkenfeld
Germany
Phone: +49 7082 7916 190
Fax: +49 7082 7916 999
ir@stratec-biomedical.de
www.stratec-biomedical.de
18.11.2010 Dissemination of a Corporate News, transmitted by DGAP -
a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: STRATEC Biomedical Systems AG
Gewerbestraße 37
75217 Birkenfeld
Deutschland
Phone: +49 (0)7082 7916 0
Fax: +49 (0)7082 7916 999
E-mail: info@stratec-biomedical.de
Internet: www.stratec-biomedical.de
ISIN: DE0007289001
WKN: 728900
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
in München, Düsseldorf, Stuttgart
End of Announcement DGAP News-Service
---------------------------------------------------------------------------